谷歌浏览器插件
订阅小程序
在清言上使用

Pos0245 protein profiling in pre-symptomatic anca-associated vasculitis individuals.

Annals of the Rheumatic Diseases(2022)

引用 0|浏览18
暂无评分
摘要
BackgroundAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare chronic relapsing condition, with unknown etiology.ObjectivesThis study was undertaken to gain insight to the molecular processes and to find potential biomarkers in blood samples collected prior to the onset of symptoms of AAV.MethodsThe National Patient Register and Cause of Death register were searched for AAV-ICD codes and linked to the registers of five biobanks. Eighty-five AAV cases were identified (34 males, 51 females) with samples >1month <10years from AAV symptom onset. For each case two controls matched for sex, age, and sampling date were included. Samples were analyzed using ELISAs for PR3- or MPO-ANCA specificities. Ninety-two protein markers were analyzed using Olink Inflammation panel, (OLINK, Uppsala, Sweden) with 73 eligible after quality control.ResultsEight protein markers were significantly altered between pre-AAV and controls, with higher levels of CCL23, CXCL5 (p< 0.01-0.05) and lower levels of Flt3L, STAMBP, ADA, TNFB, CX3CL1 and IL-15RA (p< 0.01-0.05) in the pre-AAV individuals. Nine protein markers were found significantly associated with time to symptom onset; CXCL9, CD244, VEGFA, CXCL1, TNFSF9, OPG, CSF-1, IFN-gamma and CD40 (p< 0.01-0.05). In pre-AAV individuals, six proteins were associated with MPO-ANCA-positivity compared with the MPO-ANCA-negative pre-AAV individuals which showed no overlap with the seven proteins related to PR3-ANCA-positivity.ConclusionTo our knowledge our study is the first to analyze for and identify protein markers before symptom onset in AAV. This allowed for further studies of underlying cellular and molecular mechanisms in AAV pathogenesis as well as the diversification into PR3-ANCA and MPO-ANCA subphenotypes.Disclosure of InterestsMikael Brink: None declared, Ewa Berglin: None declared, Aladdin J Mohammad Speakers bureau: Roche, Gsk, AMGEN; Vifor, Lilly, Consultant of: Roche & AMGEN, Andrey Alexeyenko: None declared, Kristina Lejon: None declared, Solbritt Rantapää Dahlqvist: None declared
更多
查看译文
关键词
pos0245 protein profiling,pre-symptomatic,anca-associated
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要